tbuckley/cabot-search huggingface dataset:
Factors associated with the quality of care at the end of life in children with cancer
Authors: J. W. Mack, J. M. Hilden, J. Watterson, H. E. Grier, J. C. Weeks, J. Wolfe
Journal: Journal of Clinical Oncology (2004)

8529 Background: Factors associated with parents' and physicians' assessments of the quality of care for children at the end of life have not been previously described. Methods: Between 1997 and 2001 we interviewed 144 parents of children who died of cancer while receiving care at the Dana-Farber Cancer Institute/Children's Hospital Boston and Children's Hospital and Clinics, St Paul and Minneapolis (overall response rate 63%). Parent assessment of the primary oncologist's overall care as “excellent” or “very good” was used as the outcome variable in a multivariable logistic regression model. A second logistic regression model used the oncologist's assessment of the child's care having gone “as well as could be expected” as the outcome. Covariates used to build both models included parent-rated aspects of communication with the oncologist and the parent's assessment of the child's symptoms and suffering. Results: Higher parent ratings of overall care were associated with providers giving clear information about what to expect in the end of life period (OR 19.90, p=0.0169), communicating in a sensitive and caring manner (OR 7.67, p=0.0095), communicating directly with the child when appropriate (OR 11.18, p=0.0011), and preparing the parent for the circumstances surrounding the child's death (OR 4.84, p=0.0339). Parent report of the child's pain and suffering were not significant correlates of parental ratings of care (p=1.0 and 0.41, respectively). Higher oncologists' ratings of care were inversely associated with the parent's report of the child's experience of pain (OR=0.15, p=0.0148) and a long period of hospitalization in the last month of life (OR 0.24, p=0.0007, for greater than 10 hospital days). Parent-rated communication factors and parent ratings of overall care were not significant correlates of oncologist-rated care. Conclusions: While physicians focus on pain and length of hospitalization as indicators of quality of care for children at the end of life, optimal communication is highly valued by parents. No significant financial relationships to disclose.
AV-65, a Novel Inhibitor of the Wnt/β-Catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells.
Authors: Hisayuki Yao, Eishi Ashihara, Rina Nagao, Shinya Kimura, Hideyo Hirai, Jeffrey W Strovel, Janak Padia, Wieslaw M Cholody, Taira Maekawa
Journal: Blood (2009)
Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression
Authors: Lara Rizzotto, Arianna Bottoni, Tzung-Huei Lai, Chaomei Liu, Pearlly S Yan, Hatice G Ozer, Rosa Lapalombella, Jennifer A. Woyach, Christopher C Oakes, James S. Blachly, Deepa Sampath
Journal: Blood (2016)
Interleukin-8 (IL8) and transforming growth-factor beta (TGF-β) as drugable biomarkers of response, progression-free survival (PFS), and overall survival (OS) with pazopanib (PZP): A phase II study in relapsed urothelial cancer (UC).
Authors: Andrea Necchi, Nadia Zaffaroni, Luigi Mariani, Patrizia Giannatempo, Nicola Nicolai, Daniele Raggi, Marzia Pennati, Carlo Morosi, Rodolfo Lanocita, Flavio Crippa, Maria Grazia Daidone, Alessandro M. Gianni, Filippo G. De Braud, Roberto Salvioni
Journal: Journal of Clinical Oncology (2012)

78 Background: Final results of INT70/09 trial of PZP in 41 multi-relapsed patients (pts) with UC reported one of the highest response-rates as 7 pts (17%) had a confirmed PR, 14 a confirmed SD (51% clinical benefit) after independent review (AACR and ASCO 2012). Final achievements on circulating biomarkers are presented. Methods: From 02/2010 to 07/2011, pts received PZP 800 mg once daily until PD or unacceptable toxicity. 50 mL of EDTA blood samples were collected at baseline (T0) and after 4wks (T1) together with disease restaging in all pts to analyze plasma levels of VEGF, sVEGFR-1,-2 and -3, c-Kit, HGF, TGF-β, IL-6, 8 and 12 by multiplex ELISA plates. Changes in marker levels were analysed with the Wilcoxon signed-rank test and matched with RECIST response with the covariance analysis. A logistic regression and Cox regression model evaluated the association with response probability, PFS and OS. Biomarker level was modelled as a continuous time varying covariate. Results: Significant increase from T0 to T1 was observed for VEGF (p&lt;0.0001), HGF (p=0.017), IL6 (p&lt;0.0129) and IL8 (p&lt;0.0013) and decrease for VEGFR2 and c-Kit (p&lt;0.0001 each). Increasing IL8 T1 level associated with lower response probability at covariance analysis (p=0.0104). Both TGF-β T0 (p=0.0019) and TGF-β T1 (p=0.0017) levels associated with PFS while elevated IL8 T0 (p=0.0170), IL8 T1 (p=0.0107) as well as TGF-β T0 (p=0.0472) and TGF-β T1 (p=0.0013) levels associated with OS. Elevated VEGF T1 also associated with shorter OS (p=0.0084) but significance was lost when jointly modelling biomarkers. Pts having IL8 T1 levels &lt; 80 pg/ml had greater response (80%) and 6-month OS (60%) probability than those with a level ≥ 80, for whom a dramatic fall was observed. Conclusions: Both IL8 and TGF-β had a prognostic value while IL8 modulation was also associated with response probability. These markers may serve to select pts most likely to get a benefit from PZP. There is a rationale for a sequence/combination with PZP and a phase II study of an anti-TGF-β receptor ALK1 moAb (PF-03446962) for refractory UC is currently recruiting (NCT01620970).
SURG-34. IMPROVED SURVIVAL WITH DECREASED WAIT TIME TO SURGERY IN GLIOBLASTOMA PATIENTS PRESENTING WITH SEIZURE
Authors: Patrick M. Flanigan, Arman Jahangiri, Ruby Kuang, Albert Truong, Sarah Choi, Alvin Chou, Michael F. McDermott, Mitchel S. Berger, Manish Aghi
Journal: Neuro-Oncology (2016)

Preoperative seizure is reported to confer favorable prognosis in glioblastoma patients. We investigated if prompter surgical intervention affects this relationship, focusing on the development of tumor growth and/or additional preoperative symptoms after seizure. Retrospective analysis of 557 patients (mean age=60.3; 42% female) undergoing first glioblastoma resection at our institution (2005-2011). Of the 557 patients, 148 (27%) had preoperative seizure(s), of which 65 (44%) had only seizure at presentation. Patients experiencing seizure as their only preoperative symptom (“seizure-only;” n=45) survived >2.5 times longer than patients who presented with seizure and then later developed additional preoperative symptoms (n=20) (“other symptoms post-seizure;” 30.4 vs. 10.9 months;p<0.0001) and patients without preoperative seizure (“no seizure”; 30.4 vs. 11.2 months;p<0.0001). Multivariate stepwise analysis revealed “seizure-only” (HR 0.51 [0.37-0.70];p<0.0001) to be independently associated with increased survival. At surgery, tumors in “seizure-only” patients were smaller than those in “other symptoms post-seizure” patients (3.1 vs. 4.3cm;p<0.01) and those in “no seizure” patients (3.1 vs. 4.8cm;p<0.0001). Radiographic preoperative tumor growth occurred more frequently in “other symptoms post-seizure” vs. “seizure-only” patients (65% vs. 9%;p<0.0001). Longer wait time from presentation to surgery was a risk factor for developing additional symptoms. Fifteen of 20 “other symptoms post-seizure” patients (75%) vs. 7 of 45 “seizure-only” patients (16%) had wait times >45 days (p<0.0001). Wait times were significantly shorter when initial presentation was to ED vs. outpatient clinic (18 vs. 60 days;p<0.01) and patients were more likely to present to ED when they had generalized seizures vs. other types (88% vs. 32%;p<0.001). Seizure as the only preoperative symptom independently improved survival, however when patients developed additional preoperative symptoms, typically due to delay in surgery, no prognostic benefit was observed. Prompt diagnosis and neurosurgical intervention is warranted in patients with seizures without other preoperative symptoms to preserve their favorable prognosis.
Abstract B08: Potential biomarkers for colorectal cancer diagnosis and prognosis
Authors: Hicham Mansour, Noureddine Bouarourou, Jean Pierre Roperch, Fouazi Habib, Mourad Said
Journal: Cancer Research (2017)

Abstract Colorectal cancer (CRC) is one of the most common cancers worldwide. It harbors several genetic and epigenetic alterations, which makes finding suitable biomarkers a challenge. CRC Cell lines are invaluable biomedical research tools for drug screening and biomarker discovery. Two emblematic cell lines for CRC were extensively used, HT29 and HCT116. We performed the whole transcriptome sequencing of these two cell lines and two normal epithelial cell lines, CR1780 and CRL18, derived from the colon as control. A methylation quantification of downregulated genes enables to screen potential biomarkers, which could be used as potential biomarkers for CRC diagnosis and prognosis. Method: Total RNA was extracted from HT29, HCT116, CR1780 and CRL18 using RNeasy Mini Kit (Qiagen). mRNA libraries were generated using TruSeq Stranded mRNA Library Prep Kit (Illumina), and high-throughput sequencing were performed using Illumina systems (Hiseq and Miseq). All reads were filtered for high-quality reads (≥Q30, adapters trimming and broken pair-reads removing). Reads alignment and genes profiling analysis were done with CLCbio software. Selected genes downregulated with p-value &amp;lt;0.001 in cancer cell lines versus normal cell lines, were evaluated for methylation in DNA extracted from tumors and autologous normal tissues from CRC patients. Results: The transcriptome analysis reveals 741 different splice variants are downregulated in both cancer cell lines HT29 and HCT116, when compared to the two normal cell lines, CR1780 and CRL18 (p-value &amp;lt;0.001). 10 relevant downregulated genes were selected, ACTG2, THY1, IGFBP3, WNT2, RAB32, SPARC, COL1A, MMP2, IGFBP3 and VIM. Interestingly, all the splice variants (10) of Vim, 7 of ATG2, 4 of THY1 and 2 of IGFBP3 were dramatically downregulated. Methylation quantification demonstrates the hypermethylation of all these 10 downregulated genes, in the tumors compared to matched normal tissues. Conclusion. At the level of mRNA expression and methylation, this study enables to screen potential biomarkers for CRC diagnosis and prognosis. Citation Format: Hicham Mansour, Noureddine Bouarourou, Jean Pierre Roperch, Fouazi Habib, Mourad Said. Potential biomarkers for colorectal cancer diagnosis and prognosis. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr B08.
Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia
Authors: Jatinder K Lamba, Stanley Pounds, Xueyuan Cao, Susana C. Raimondi, James R. Downing, Raul C Ribeiro, Jeffrey Rubnitz
Journal: Blood (2015)
MPTH-20. PREOPERATIVE SERUM microRNA PROFILING AS A DIAGNOSTIC TOOL IN GLIOMA
Authors: Andrew Morokoff, Iwan Bennett, Lucy Paradiso, Rod Luwor, Michael Wong, Rachel Koldej, Jason Li, Chenkai Ma, Kate Drummond, Stanley Stylli, Andrew Kaye, Tali Siegal
Journal: Neuro-Oncology (2016)

Current diagnosis of glioma is based on clinical suspicion, magnetic resonance imaging (MRI) and ultimately surgical biopsy based on WHO criteria for neuropathology. Blood sampling for circulating assessment of biomarkers is a potentially valuable method that could supplement diagnostic criteria by providing pre-operative molecular information. We previously showed that miR-10b and miR-21 were significantly upregulated in untreated high-grade glioma patients compared to healthy controls. We hypothesized that largescale miRNA profiling could improve diagnostic discrimination across all grades of glioma. Pre-operative serum samples were collected from 91 glioma patients (45 GBM, 46 low grade glioma) presenting to the Royal Melbourne Hospital between 2009 and 2014, and compared to 20 healthy controls. Profiling of 800 microRNAs was performed by Nanostring ® v.3 analysis of isolated total serum RNA. Statistical output and heatmaps were generated using nSolver and R packages. miRNA profiles differed significantly between GBM, LGG and healthy controls. Highly differentially upregulated miRs included miR-21, miR-29a and miR-363. miR-21 and miR-29a were significantly associated with overall survival. A 19-miRNA gene classifier incorporating miRs with p<0.01 and log-fold change >0.5 in either direction was able to discriminate strongly between GBM and LGG. Largescale profiling of miRNA expression levels in serum shows promise for discovery of diagnostic and prognostic circulating biomarkers. These results require validation in prospective data sets.
Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.
Authors: Shaji Kumar, Luis F Porrata, Stephen M. Ansell, Joseph P Colgan, Betsy LaPlant, Morie A Gertz, David J Inwards, Patrick B Johnston, Thomas Haberman, Ivana N Micallef, Grzegorz S. Nowakowski, Thomas E. Witzig
Journal: Blood (2010)
Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-cell non-Hodgkin's lymphoma (B-NHL)
Authors: K. Tobinai, T. Watanabe, M. Ogura, Y. Morishima, K. Itoh, T. Igarashi, T. Hotta, T. Kinoshita, S. Mori, Y. Ohashi
Journal: Journal of Clinical Oncology (2004)

6577 Background: R-CHOP is regarded as the best available treatment for untreated patients (pts) with indolent and aggressive B-NHL; however, the optimal combination schedule in indolent B-NHL remains unknown. Methods: Previously untreated pts with indolent B-NHL of advanced stages were randomly allocated to the concurrent arm (Arm C) or the sequential arm (Arm S). All pts received 6 cycles of standard CHOP every 3 weeks. In addition, Arm C received R at 375 mg/m2, 6 times, 2 days prior to each cycle of CHOP, whereas Arm S received R at 375 mg/m2, weekly 6 times, following 6 cycles of CHOP. Pts were monitored for clinical response by the International Workshop Criteria, molecular response by PCR assay for bcl-2 rearrangement in bone marrow and peripheral blood, and adverse events for at least 3 years or until progression. The primary endpoint was the overall response rate (ORR). Results: Between July 1999 and July 2000, a total of 69 pts were enrolled, and 66 (Arm C, 32; Arm S, 34) of them were eligible. The two arms were comparable in major prognostic features. A central pathology review revealed follicular lymphoma accounted for 95%. ORR represented 94% (30/32; 95% confidence interval [CI], 79–99%) including 81% of complete response (CR) in Arm C and 97% (33/34; 95% CI, 85–100%) including 85% of CR in Arm S. The time to achieving response in 75% of the pts was 66 days (95% CI, 63–76 days) in Arm C and 127 days (95% CI, 66–135 days) in Arm S (P=0.099). Molecular response occurred more promptly in Arm C. Grade 4 hematologic toxicities were observed in 85% in Arm C and 70% in Arm S, and grade 3 or greater non-hematologic toxicities in 19% in Arm C and in 9% in Arm S. Both arms were well tolerated. The median progression-free survival (PFS) time was 864+ days in Arm C and 920+ days in Arm S (P=0.322). Eighteen pts (58%) in Arm C and 23 pts (70%) in Arm S were continuously progression-free. Conclusions: R-CHOP is highly effective for untreated indolent B-NHL either by concurrent or sequential combination. The time to response is more prompt with the concurrent combination, whereas PFS appears to be longer with the sequential combination. No significant financial relationships to disclose.
NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
Authors: Erin K Hertlein, Timothy L Chen, David M Lucas, Nikhil Gupta, Jessica MacMurray, Virginia M. Goettl, Amy M. Lehman, Amy J. Johnson, John C Byrd
Journal: Blood (2015)
Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.
Authors: Andreas H. Sarris, Umberto Vitolo, Emanuele Zucca, George Z. Rassidakis, Jeffrey Medeiros, Maria Giuseppina Cabras, Alice Di Rocco, Barbara Pro, Mary K. Gospodarowicz, Franco Cavalli
Journal: Blood (2006)
Endomyocardial biopsy findings in pediatric patients with post myocarditic state.
Authors: Tsutomu Saji, Norio Matsuo, Reiko Hashiguchi, Keiko Sato, Ryuichi Itoh, Tetsurou Umezawa, Shin Yamamoto, Yoshimasa Yabe, Nobuya Koyama, Hiroaki Sagawa
Journal: Circulation (1986)

Endomyocardial biopsy was performed on eight children 5 to 12 years old, who were in post myocarditic state. They were evaluated within 2 to 25 months (mean lyr and 1 m) after the onset of the symptoms. Two of the patients developed heart failure and six patients developed other cardiac manifestations such as syncope, palpitation or EG abnormalities at onset. Definite elevation of viral antibody titer was observed in four patients. Radio-nuclide angiography was also performed in all eight patients. An abnormal perfusion area was observed in six patients as a focal hypoperfusion area by Tl-201 myocardial imaging. Ejection fraction was examined by Tc-99m-HSA gated equilibrium ventriculography. LVEF was reduced in 3 patients and RVEF was reduced in 2 patients. Judging from the histopathological findings, these patients were divided into three categories : chronic or smoldering myocarditis (3 patients) ; healing or healed myocarditis (4 patients); and post myocarditic hypertrophy (1 patient). Measurement of left ventricular function was obtained by cardiac catheterization and left ventriculography (LVG), which revealed some abnormal findings such as increased left ventricular mass index, increased left ventricular end diastolic volume index (LVEDVI) and reduced left ventricular ejection fraction (LVEF). Therefore, endomyocardial biopsy findings of pediatric patients in a post myocarditic state reveal certain histopathological abnormalities even in the long-term follow-up period in the absence of cardiac dysfunction.
STMC-14. GLIOBLASTOMA CANCER STEM CELLS UNDERGO DYNAMIC STATE TRANSITIONS
Authors: Anne Dirkse, Nicolaas H. C. Brons, Thomas Buder, Andreas Deutsch, Sonia Leite, Nicolas Sauvageot, Stephen Senn, Christel Herold-Mende, Anna Golebiewska, Simone Niclou
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) is a highly malignant brain tumor where no curative treatment is available. According to the cancer stem cell (CSC) hypothesis GBMs rely on a small subpopulation of cancer cells with stem-like properties responsible for tumor progression and recurrence. Recent experimental data from GBM and other cancers however suggest that CSCs cannot be defined by specific marker expression and may in fact not be a stable entity but a population of cells adapting to a changing microenvironment. We have previously shown that glioma CSCs do not represent a genetically homogenous population. Here we examined inter- and intra-tumoral heterogeneity of CSCs and their adaptation capacity based on stem cell-associated marker expression profiles. Tumor cell subpopulations were classified based on their expression of four chosen cell membrane markers (CD133, CD15, A2B5 and CD44) using multicolor flow cytometry. 16 subpopulations were separated and analyzed for their self-renewal capacity and their ability to reform the original heterogeneous cell population. Mathematical modelling was applied to calculate state transitions between phenotypes and predict the adaptive response of CSCs. Similar to GBM biopsies, we observed markers to be heterogeneously expressed in glioma stem-like cells and primary cultures. All analyzed tumor cell subpopulations were able to proliferate and carried stem-cell properties including self-renewal potential. Moreover all subpopulations were able to adapt their marker profiles to give rise to the original subpopulations. Interestingly, mathematical modeling revealed a different propensity in reforming the original heterogeneity between subpopulations over time, which was independent of their proliferation index. Our results suggest that glioma CSCs do not represent a stable entity and that intra-tumoral heterogeneity in GBM at least partially results from a high cellular adaptation capacity. This implies that glioma treatment approaches should take into account the strong propensity of cancer cells for phenotypic state transitions.
Acute Myeloid Leukemia Lysate Loaded Dendritic Cells Exhibit Significant Phagocytic Function and Elicit Antigen-Specific Immune Response.
Authors: Dongxia Xing, William K. Decker, Hong Yang, Simon N. Robinson, Michael W. Thomas, Sufang Li, Ting Niu, Harry Segall, John D. McMannis, Richard E. Champlin, Elizabeth J. Shpall
Journal: Blood (2004)
Adoptive Immunotherapy with Donor Allodepleted T Cells.
Authors: L. Dal Cortivo, N. Mahlaoui, C. Picard, B. Neven, I. Andre-Schmutz, J.M. Luby, C. Martinache, T. Paquet, F. Ledeist, A. Fischer, M. Cavazzana-Calvo
Journal: Blood (2005)
Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
Authors: A.-C. Hardy-Bessard, F. Brocard, M. Leheurteur, A. Melis, J. Dauba, A. Lortholary, B. You, E. Guardiola, J. Grenier, J. Martin-Babau, J. Meunier, P. Follana, A.-M. Savoye, A. Mercier-Blas, A. Marti, R. Despax, N. Barbier, N. Gane, P. Ardisson, C. Segura-Djezzar
Journal: Annals of Oncology (2016)
Genotype-Phenotype Correlations in Patients with Hereditary Angioedema
Authors: Luana S.M. Maia, Mariana Paes Leme Ferriani, Fernanda Leonel Nunes, Maria Fernanda Ferraro, Marina Mendonca Dias, Faradiba Sarquis Serpa, Antonio Abilio Motta, Solange Rodrigues Valle, Wilson Araujo Silva-Jr, Davi Casale Aragon, Willy Sarti, Luisa Karla P. Arruda, Adriana S. Moreno
Journal: Journal of Allergy and Clinical Immunology (2017)
Efficacy and tolerability of first-line chemotherapy in elderly patients (age ≥70 years) with metastatic gastric cancer: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)
Authors: M.N. Aldemir, M. Turkeli, B. Hacioglu, A. Sakin, E. Yaman, E. Coban, D. Koca, M. Karaca, M. Simsek, A. Bahceci, E. Sen, T. Eren, B.ö Aliustaoglu, T. Sakalar, N.O. Kalkan, G. Aktas, M. Bilici, S. Turhal, M. Benekli, S.B. Tekin
Journal: Annals of Oncology (2016)
PTH and Bortezomib Suppress Growth of Primary Human Myeloma through Increased Bone Formation In Vivo.
Authors: Angela Pennisi, Wen Ling, Paul Perkins, Rinku Saha, Xin Li, Bart Barlogie, Guido Tricot, Maurizio Zangari, Shmuel Yaccoby
Journal: Blood (2006)